Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.43 |
| ▸ | CHUK | O15111 | 5/20 | 0.43 |
| ▸ | BRD4 | O60885 | 13/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CDK11B | P21127 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.36 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.36 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.36 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496643 | 0.90 | IKBKB (0.39) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3495414 | 0.85 | IKBKB (0.41) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3494460 | 0.84 | IKBKB (0.43) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3496962 | 0.84 | IKBKB (0.40) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3496373 | 0.82 | IKBKB (0.42) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3496915 | 0.82 | IKBKB (0.40) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3496169 | 0.82 | IKBKB (0.40) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3494405 | 0.82 | FYN (0.46) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3496574 | 0.81 | IKBKB (0.39) | IKBKBCHUKBRD4FYNCDK11B | |
| SCHEMBL3494696 | 0.81 | IKBKB (0.40) | IKBKBCHUKBRD4FYNCDK11B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| EP-2155750-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | Mutabilis SA (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | DLAT, DLST, DNTT | IKBKB 945/4885CHUK 253/4885BRD4 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.